33 results on '"Xiao, Mingzhe"'
Search Results
2. SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC
3. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report
4. Eco-Friendly Shield Muck-Incorporated Grouting Materials: Mix Optimization and Property Evaluation for Silty Clay Tunnel Construction.
5. A remarkable clinical response to immune checkpoint inhibitors of MSI-H high grade Mucoepidermoid carcinoma of the parotid gland with multiple metastases in the abdominal cavity
6. Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment
7. PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non‐small cell lung cancer
8. SIRT4-Catalyzed Deacetylation of Axin1 Modulates the Wnt/β-Catenin Signaling Pathway
9. Long non‐coding RNA TDRG1 aggravates colorectal cancer stemness by binding with miR‐873‐5p to upregulate PRKAR2
10. Genomic signatures in young and old Chinese patients with bone and soft tissue tumors.
11. PAPPA2 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC and SKCM.
12. ANK2 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC.
13. Slit mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC.
14. XIRP2 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC.
15. Comprehensive molecular characterization of Chinese patients with biliary tract cancers.
16. NPAP1 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC.
17. The predictive values of POTEE mutations for response to immune checkpoint inhibitors in lung adenocarcinoma.
18. Short-term efficacy of furmonertinib in treatment of NSCLC patients with EGFR exon20 insertion.
19. Genomic characterization of primary cervical cancer and lung metastasis.
20. Immune-suppressive microenvironment was revealed from NSCLC patients with hyperprogressive disease (HPD) from immunotherapy.
21. DYNC2H1 Mutation as an indicator stratified patients benefit from Immune Checkpoint Inhibitors in NSCLC.
22. WDR49 mutation as a novel predictive biomarker in patients with non–small cell lung cancer with immune checkpoint inhibitors.
23. Clinical significance of next generation sequencing (NGS) in Chinese patients with relapsed/refractory Wilm’s tumor.
24. ZFHX4 mutation as a novel predictive biomarker for immune checkpoint blockade in non-small cell lung cancer.
25. Locally advanced undifferentiated sarcomatoid carcinoma of the right maxillary sinus with PDCD6-TERT fusion: A rare case report
26. NOTCH1 Mutation Impairs the Adaptive Immune Response, Leading to Decreased Relapse-Free Survival In Patients with Resected T1-2N0 Laryngeal Cancer
27. Long non‐coding RNATDRG1 aggravates colorectal cancer stemness by binding with miR‐873‐5p to upregulate PRKAR2.
28. High frequency of germline mutations in DDR associated genes SLX4, MSH6, CDK4, TSC2, and BRCA2 might contribute to the occurrence of MPLC.
29. Homologous recombination-related (HRR) gene mutation profiling and the association with TMB in Chinese patients with urological cancer.
30. Homologous recombination-related (HRR) gene mutation profiling and the association with TMB in Chinese patients with pancreatic cancer.
31. Homologous recombination-related (HRR) gene mutation profiling and the association with TMB in Chinese patients with esophageal and gastric cancer.
32. Dynamic monitoring of ctDNA to predict response to immunotherapy plus chemotherapy in BTC.
33. LIF Promotes Sec15b-Mediated STAT3 Exosome Secretion to Maintain Stem Cell Pluripotency in Mouse Embryonic Development.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.